Scientific Expertise Built for Radiopharmaceutical Development
Adracco was created to give radiopharmaceutical developers more direct access to the expertise, infrastructure, and practical guidance needed to accelerate promising ideas toward clinical development.
To equip radiopharmaceutical developers with direct access to world-class scientific expertise, specialized preclinical infrastructure, and practical development guidance, facilitating confident progression from idea to IND.
Our Mission
Our Vision
Adracco is the trusted partner for radiopharmaceutical developers, transforming promising ideas into clinical therapies through solid science, clear and practical guidance, and more accessible preclinical infrastructure.
WHY ADRACCO EXISTSBridging the Gap Between Promising Science and IND-Ready Development
Many radiopharmaceutical programs begin with compelling scientific potential, but developers can quickly face uncertainty around what to do next. The path from concept to IND requires specialized infrastructure, experienced interpretation, and expert-led execution. Adracco exists to make that path clearer, more practical, and more accessible.
Expert Guidance Backed by Specialized Capabiliities
Adracco brings together recognized radiopharmaceutical expertise and complete preclinical infrastructure to help teams execute the right studies, answer the right development questions, and generate data that supports confident decision-making.
Meet the Experts Behind Adracco
The radiopharmaceutical development experts who lead Adracco understand what it takes to move a promising candidate from early concept toward IND readiness.
With deep experience across preclinical development, imaging, radiolabeling, study design, and translational strategy, Adracco brings hands-on guidance to each stage of the development pathway.
Benjamin Larimer, PhD
Ben Larimer is a radiopharmaceutical imaging researcher and translational scientist with expertise in preclinical and clinical oncology imaging. As CEO of Adracco and a faculty member at the University of Alabama at Birmingham, Ben leads the company’s strategic direction, sponsor relationships, and program coordination, ensuring each engagement is oriented around the right scientific and regulatory next step.
Suzy Lapi, PhD
Suzanne Lapi is a Professor of Radiology and Chemistry at UAB and Director of the UAB Cyclotron Facility and Radiochemistry Laboratory. A nationally recognized authority in isotope production, PET radiochemistry, and translational imaging probe development, Dr. Lapi brings decades of experience developing novel radiopharmaceuticals from early concept through IND-enabling studies across oncology, immunology, and neuroscience.
Colin G. Miller, PhD, FIPEM, CSci
Colin Miller is a clinical development strategist with deep expertise in medical imaging, radiopharmaceuticals, and nuclear medicine. His background spans clinical trial design, development strategy, and translational imaging across multiple therapeutic areas, bringing the strategic perspective needed to guide programs from preclinical proof-of-concept through clinical development planning.
